Acasti names special advisor
This article was originally published in Scrip
Executive Summary
Laval, Quebec-based Acasti Pharma, an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies, has named Jerald J Wenker as a special advisor to its board of directors. Mr Wenker – who is currently president and COO of Dermalogica, a skin care company based in the US – has also accepted a nomination for election to serve on Acasti's board at the next annual meeting to be held in 2014.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.